Literature DB >> 17290054

Lung cancer incidence in never smokers.

Heather A Wakelee1, Ellen T Chang, Scarlett L Gomez, Theresa H Keegan, Diane Feskanich, Christina A Clarke, Lars Holmberg, Lee C Yong, Laurence N Kolonel, Michael K Gould, Dee W West.   

Abstract

PURPOSE: Lung cancer is a leading cause of cancer death worldwide. Although smoking remains the predominant cause of lung cancer, lung cancer in never smokers is an increasingly prominent public health issue. However, data on this topic, particularly lung cancer incidence rates in never smokers, are limited.
METHODS: We reviewed the existing literature on lung cancer incidence and mortality rates among never smokers and present new data regarding rates in never smokers from the following large, prospective cohorts: Nurses' Health Study; Health Professionals Follow-Up Study; California Teachers Study; Multiethnic Cohort Study; Swedish Lung Cancer Register in the Uppsala/Orebro region; and First National Health and Nutrition Examination Survey Epidemiologic Follow-Up Study.
RESULTS: Truncated age-adjusted incidence rates of lung cancer among never smokers age 40 to 79 years in these six cohorts ranged from 14.4 to 20.8 per 100,000 person-years in women and 4.8 to 13.7 per 100,000 person-years in men, supporting earlier observations that women are more likely than men to have non-smoking-associated lung cancer. The distinct biology of lung cancer in never smokers is apparent in differential responses to epidermal growth factor receptor inhibitors and an increased prevalence of adenocarcinoma histology in never smokers.
CONCLUSION: Lung cancer in never smokers is an important public health issue, and further exploration of its incidence patterns, etiology, and biology is needed.

Entities:  

Mesh:

Year:  2007        PMID: 17290054      PMCID: PMC2764546          DOI: 10.1200/JCO.2006.07.2983

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  69 in total

1.  Epidemiology of bronchioloalveolar carcinoma: improvement in survival after release of the 1999 WHO classification of lung tumors.

Authors:  Jason A Zell; S-H Ignatius Ou; Argyrios Ziogas; Hoda Anton-Culver
Journal:  J Clin Oncol       Date:  2005-11-20       Impact factor: 44.544

Review 2.  Cancer surveillance research: a vital subdiscipline of cancer epidemiology.

Authors:  Sally L Glaser; Christina A Clarke; Scarlett L Gomez; Cynthia D O'Malley; David M Purdie; Dee W West
Journal:  Cancer Causes Control       Date:  2005-11       Impact factor: 2.506

3.  Erlotinib in lung cancer - molecular and clinical predictors of outcome.

Authors:  Ming-Sound Tsao; Akira Sakurada; Jean-Claude Cutz; Chang-Qi Zhu; Suzanne Kamel-Reid; Jeremy Squire; Ian Lorimer; Tong Zhang; Ni Liu; Manijeh Daneshmand; Paula Marrano; Gilda da Cunha Santos; Alain Lagarde; Frank Richardson; Lesley Seymour; Marlo Whitehead; Keyue Ding; Joseph Pater; Frances A Shepherd
Journal:  N Engl J Med       Date:  2005-07-14       Impact factor: 91.245

4.  Erlotinib in previously treated non-small-cell lung cancer.

Authors:  Frances A Shepherd; José Rodrigues Pereira; Tudor Ciuleanu; Eng Huat Tan; Vera Hirsh; Sumitra Thongprasert; Daniel Campos; Savitree Maoleekoonpiroj; Michael Smylie; Renato Martins; Maximiliano van Kooten; Mircea Dediu; Brian Findlay; Dongsheng Tu; Dianne Johnston; Andrea Bezjak; Gary Clark; Pedro Santabárbara; Lesley Seymour
Journal:  N Engl J Med       Date:  2005-07-14       Impact factor: 91.245

5.  Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer).

Authors:  Nick Thatcher; Alex Chang; Purvish Parikh; José Rodrigues Pereira; Tudor Ciuleanu; Joachim von Pawel; Sumitra Thongprasert; Eng Huat Tan; Kristine Pemberton; Venice Archer; Kevin Carroll
Journal:  Lancet       Date:  2005 Oct 29-Nov 4       Impact factor: 79.321

6.  TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers.

Authors:  Florence Le Calvez; Anush Mukeria; Jay D Hunt; Olaf Kelm; Rayjean J Hung; Philippe Tanière; Paul Brennan; Paolo Boffetta; David G Zaridze; Pierre Hainaut
Journal:  Cancer Res       Date:  2005-06-15       Impact factor: 12.701

7.  Contemporary lung cancer trends among U.S. women.

Authors:  Ahmedin Jemal; Elizabeth Ward; Michael J Thun
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-03       Impact factor: 4.254

Review 8.  Epidemiology of lung cancer: looking to the future.

Authors:  Anthony J Alberg; Malcolm V Brock; Jonathan M Samet
Journal:  J Clin Oncol       Date:  2005-05-10       Impact factor: 44.544

9.  CYP1A1 and CYP1B1 polymorphisms and risk of lung cancer among never smokers: a population-based study.

Authors:  A S Wenzlaff; M L Cote; C H Bock; S J Land; S K Santer; D R Schwartz; A G Schwartz
Journal:  Carcinogenesis       Date:  2005-07-28       Impact factor: 4.944

10.  Updated information on risk factors for lung cancer: findings from the JACC Study.

Authors:  Kenji Wakai; Masahiko Ando; Kotaro Ozasa; Yoshinori Ito; Koji Suzuki; Yoshikazu Nishino; Shin-ichi Kuriyama; Nao Seki; Takaaki Kondo; Yoshiyuki Watanabe; Yoshiyuki Ohno; Akiko Tamakoshi
Journal:  J Epidemiol       Date:  2005-06       Impact factor: 3.211

View more
  176 in total

1.  Targeting the estrogen pathway for the treatment and prevention of lung cancer.

Authors:  Timothy F Burns; Laura P Stabile
Journal:  Lung Cancer Manag       Date:  2014-02-01

2.  Difference in survival and prognostic factors between smokers and never-smokers with advanced non-small-cell lung cancer.

Authors:  Shiro Tanaka; Kazuhiro Yanagihara; Satoshi Tamaru; Satoshi Teramukai; Toshiyuki Kitano; Masanori Fukushima
Journal:  Int J Clin Oncol       Date:  2011-11-10       Impact factor: 3.402

3.  Physical activity and sedentary behavior in relation to lung cancer incidence and mortality in older women: The Women's Health Initiative.

Authors:  Ange Wang; FeiFei Qin; Haley Hedlin; Manisha Desai; Rowan Chlebowski; Scarlett Gomez; Charles B Eaton; Karen C Johnson; Lihong Qi; Jean Wactawski-Wende; Catherine Womack; Heather A Wakelee; Marcia L Stefanick
Journal:  Int J Cancer       Date:  2016-11-15       Impact factor: 7.396

Review 4.  Sex-specific lung diseases: effect of oestrogen on cultured cells and in animal models.

Authors:  Bosung Shim; Gustavo Pacheco-Rodriguez; Jiro Kato; Thomas N Darling; Martha Vaughan; Joel Moss
Journal:  Eur Respir Rev       Date:  2013-09-01

5.  Association between the CpG island methylator phenotype and its prognostic significance in primary pulmonary adenocarcinoma.

Authors:  Young Wha Koh; Sung-Min Chun; Young-Soo Park; Joon Seon Song; Geon Kook Lee; Shin Kwang Khang; Se Jin Jang
Journal:  Tumour Biol       Date:  2016-02-11

6.  Cancer incidence in the Agricultural Health Study after 20 years of follow-up.

Authors:  Catherine C Lerro; Stella Koutros; Gabriella Andreotti; Dale P Sandler; Charles F Lynch; Lydia M Louis; Aaron Blair; Christine G Parks; Srishti Shrestha; Jay H Lubin; Paul S Albert; Jonathan N Hofmann; Laura E Beane Freeman
Journal:  Cancer Causes Control       Date:  2019-02-25       Impact factor: 2.506

7.  Reproductive factors and risk of lung cancer in female textile workers in Shanghai, China.

Authors:  Lisa G Gallagher; Karin A Rosenblatt; Roberta M Ray; Wenjin Li; Dao L Gao; Katie M Applebaum; Harvey Checkoway; David B Thomas
Journal:  Cancer Causes Control       Date:  2013-04-13       Impact factor: 2.506

8.  Invited commentary: the etiology of lung cancer in men compared with women.

Authors:  Anthony J Alberg; Kristin Wallace; Gerard A Silvestri; Malcolm V Brock
Journal:  Am J Epidemiol       Date:  2013-02-20       Impact factor: 4.897

9.  Prognostic models to predict survival in non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin with or without bevacizumab.

Authors:  Tien Hoang; Suzanne E Dahlberg; Alan B Sandler; Julie R Brahmer; Joan H Schiller; David H Johnson
Journal:  J Thorac Oncol       Date:  2012-09       Impact factor: 15.609

10.  Secretomes are a potential source of molecular targets for cancer therapies and indicate that APOE is a candidate biomarker for lung adenocarcinoma metastasis.

Authors:  Zan Liu; Yuan Gao; Fengxia Hao; Xiaomin Lou; Xiuwei Zhang; Yang Li; Di Wu; Ting Xiao; Longhai Yang; Qingchang Li; Xueshan Qiu; Enhua Wang
Journal:  Mol Biol Rep       Date:  2014-08-07       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.